PA
HCAT icon

Probity Advisors’s Health Catalyst HCAT Stock Holding History

Probity Advisors’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,650
Closed -$14.8K – 236
2026
Q1 		$14.8K Sell
11,650
-11,725
-50% -$22.1K ﹤0.01% 230
2025
Q4 		$55.9K Sell
23,375
-21,786
-48% -$59.6K 0.01% 232
2025
Q3 		$129K Buy
45,161
+7,671
+20% +$26.3K 0.02% 234
2025
Q2 		$141K Buy
37,490
+1,177
+3% +$4.63K 0.02% 229
2025
Q1 		$164K Buy
36,313
+5,621
+18% +$29.7K 0.03% 226
2024
Q4 		$217K Buy
30,692
+7,647
+33% +$60.9K 0.04% 222
2024
Q3 		$188K Buy
23,045
+2,699
+13% +$19.5K 0.04% 227
2024
Q2 		$130K Buy
20,346
+6,304
+45% +$40.5K 0.03% 207
2024
Q1 		$106K Buy
+14,042
New +$128K 0.02% 209

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Probity Advisors's HCAT Position: Q2 2026 in Review

Probity Advisors sold out of Health Catalyst (HCAT) in Q2 2026, closing a stake of 11,650 shares — an estimated $14.8K sold.

Probity Advisors first reported a position in HCAT in Q1 2024 and held it in 9 quarters. The position peaked at $217K in Q4 2024. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Probity Advisors reported no remaining Health Catalyst position as of Q2 2026 after selling out during the quarter.
  • Probity Advisors sold 11,650 Health Catalyst shares in Q2 2026, an estimated $14.8K.
  • Probity Advisors first reported a position in Health Catalyst in Q1 2024 and held it in 9 quarters.
  • Probity Advisors's Health Catalyst position peaked at $217K in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.